Jasper Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JSPR research report →
Companyjaspertherapeutics.com
Jasper Therapeutics, Inc. , a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.
- CEO
- Jeetinder Singh Mahal
- IPO
- 2020
- Employees
- 64
- HQ
- Redwood City, CA, US
Price Chart
Valuation
- Market Cap
- $14.18M
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.07
- EV/EBITDA
- -0.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -523.04%
- ROIC
- -564.18%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-75,801,000 · -6.36%
- EPS
- $-3.95 · 19.22%
- Op Income
- $-80,518,000
- FCF YoY
- -22.19%
Performance & Tape
- 52W High
- $7.19
- 52W Low
- $0.62
- 50D MA
- $0.98
- 200D MA
- $1.77
- Beta
- 3.08
- Avg Volume
- 407.25K
Get TickerSpark's AI analysis on JSPR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 6, 26 | Mahal Jeetinder Singh | other | 500,000 |
| Jan 2, 26 | MARTELL RON | other | 234,000 |
| Jan 2, 26 | Mahal Jeetinder Singh | other | 90,000 |
| Jan 2, 26 | CROSS HERB | other | 90,000 |
| Sep 22, 25 | WIGGANS THOMAS G | buy | 41,000 |
| Sep 22, 25 | WIGGANS THOMAS G | buy | 41,000 |
| Sep 22, 25 | Lucas Svetlana | buy | 20,000 |
| Sep 22, 25 | Lucas Svetlana | buy | 20,000 |
| Sep 22, 25 | MARTELL RON | buy | 41,000 |
| Sep 22, 25 | MARTELL RON | buy | 41,000 |
Our JSPR Coverage
We haven't published any research on JSPR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate JSPR Report →